BioSpecifics Technologies (BSTC) (click here for most recent presentation) is focused on the development of injected biological agent (collagenase/XIAFLEX) for a variety of indications in collaboration with Auxilium Pharma (AUXL) as a marketing and development partner in an agreement that results in BSTC receiving royalties, mark-up on cost of goods sold and licensing revenue.
CLINICAL And REGULATORY CATALYSTS:
XIAFLEX (AA4500) (collagenase clostridium histolyticum) is being evaluated in multiple clinical trials and also has a near-term FDA catalyst in the form of a 6-September PDUFA data for a supplemental Biologics License Application (sBLA) seeking the FDA approved label for the product.
The sBLA is undergoing a standard review by the FDA and...
Only subscribers can access this article, which is part of the PRO research library covering 3,570 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: